Drug Trial Radar · NCT07214311
Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Feb 3, 2026
Primary completion
Sep 2028
Study completion Sep 2028
Sponsor
- Lead sponsor
- PeptilogicsIndustry
- Sponsor type
- Industry
- First posted
- Oct 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate whether the investigational drug PLG0206 can help reduce recurrence of infection in adults who have undergone total knee replacement and are receiving a DAIR (Debridement, Antibiotics, and Implant Retention) surgical procedure to treat a Prosthetic Joint Infection (PJI). The study will also assess the safety of PLG0206 when used as an irrigation solution during the DAIR procedure. Participants will receive either PLG0206 or a placebo (an inactive substance that looks like the investigational drug), in addition to standard of care treatments. All participants will be monitored for approximately one year following their DAIR procedure.
Conditions
- Prosthetic-joint Infection
Interventions
PLG0206Drug
PLG0206 Solution
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction in Treatment Failure Post DAIRTime frame: From treatment through 12 months
Locations
24 sites in 2 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Pensacola, Florida · Recruiting
Clinical Trial Site
Sarasota, Florida · Recruiting
Clinical Trial Site
Tamarac, Florida · Recruiting
Clinical Trial Site
Shreveport, Louisiana · Recruiting
Clinical Trial Site
Baltimore, Maryland · Withdrawn
Clinical Trial Site
Boston, Massachusetts · Recruiting
Clinical Trial Site
New York, New York · Withdrawn
Clinical Trial Site
Leland, North Carolina · Recruiting
Clinical Trial Site
Cincinnati, Ohio · Recruiting
Clinical Trial Site
Cleveland, Ohio · Recruiting
Clinical Trial Site
Columbus, Ohio · Recruiting
Clinical Trial Site
Pittsburgh, Pennsylvania · Recruiting
Clinical Trial Site
Dallas, Texas · Recruiting
Clinical Trial Site
Edinburg, Texas · Recruiting
Clinical Trial Site
Katy, Texas · Recruiting
Clinical Trial Site
Salt Lake City, Utah · Recruiting
Clinical Trial Site
Morgantown, West Virginia · Recruiting
Clinical Trial Site
Cambridge, Cambridgeshire, United Kingdom · Recruiting
Clinical Trial Site
Edinburgh, Lothian, United Kingdom · Recruiting
Clinical Trial Site
Norwich, Norfolk, United Kingdom · Recruiting
Clinical Trial Site
Sheffield, South Yorkshire, United Kingdom · Recruiting
Clinical Trial Site
Clydebank, Strathclyde, United Kingdom · Recruiting
Clinical Trial Site
Coventry, West Midlands, United Kingdom · Recruiting
Clinical Trial Site
Leeds, West Yorkshire, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.